# Anteromedial Globus Pallidus Internus Deep Brain Stimulation for Gilles de la Tourette Syndrome: A Two-Case Report and Review of the Literature

**Authors:** Tomislav Felbabić, Rok Berlot, Maja Trošt, Dejan Georgiev, Mitja Benedičič

PMC · DOI: 10.3390/neurolint18020021 · Neurology International · 2026-01-25

## TL;DR

This paper reports on two patients with Tourette syndrome who improved after deep brain stimulation in a specific brain region, suggesting it could be a promising treatment.

## Contribution

The first two cases of deep brain stimulation in the anteromedial globus pallidus internus for Tourette syndrome in Slovenia.

## Key findings

- Both patients showed significant reduction in tic severity over 18 months of follow-up.
- Yale Global Tic Severity Scale scores decreased substantially in both cases.
- The results suggest deep brain stimulation may be a viable treatment for severe Tourette syndrome.

## Abstract

Background: Gilles de la Tourette syndrome is a neurobehavioral disorder that typically begins in childhood, subsides during puberty, and may reappear in adolescence. Treatment is primarily conservative, involving psychological and pharmacological therapy. Patients who do not respond to conservative therapy may be treated with deep brain stimulation, although this remains an experimental treatment. Methods: In this two-case report we present the first two cases of patients with Gilles de la Tourette syndrome in Slovenia treated with deep brain stimulation of the anteromedial globus pallidus internus. Results: Over an 18-month follow-up period, we observed an improvement in both cases. In the first case, the Yale Global Tic Severity Scale score decreased from 71 (17 for motor tics, 14 for phonic tics, and 40 on the impairment scale) to 44 points (12 motor, 12 phonic, and 20 impairment). In the second case, the score decreased from 72 (16 motor, 16 phonic, and 40 impairment) to 38 points (8 motor, 10 phonic, and 20 impairment). Conclusions: Deep brain stimulation could be a promising treatment for this disorder. However, further research is needed to determine the most suitable patients and targets.

## Linked entities

- **Diseases:** Gilles de la Tourette syndrome (MONDO:0007661)

## Full-text entities

- **Diseases:** dystonia (MESH:D004421), injury to (MESH:D014947), dystonic movements (MESH:C536300), violent extensions (MESH:D000079822), Parkinson's disease (MESH:D010300), aortic coarctation (MESH:D001017), psychiatric (MESH:D001523), anxiety (MESH:D001007), asthma (MESH:D001249), nausea (MESH:D009325), weight gain (MESH:D015430), mood disorder (MESH:D019964), neurobehavioral disorder (MESH:D019954), dysarthria (MESH:D004401), fatigue (MESH:D005221), hyperkinetic (MESH:D006948), neurological deficits (MESH:D009461), cervical myelopathy (MESH:D002575), vomiting (MESH:D014839), symptoms (MESH:D012816), spasms (MESH:D013035), infections (MESH:D007239), GTS (MESH:D005879), restlessness (MESH:D011595), dizziness (MESH:D004244), stuttering (MESH:D013342), OCD (MESH:D009771), depression (MESH:D003866), dyskinesias (MESH:D004409), paresthesia (MESH:D010292), Tic Symptom (MESH:D020323), hypomania (MESH:D000087122)
- **Chemicals:** haloperidol (MESH:D006220), duloxetine (MESH:D000068736), Clonazepam (MESH:D002998), paroxetine (MESH:D017374), aspirin (MESH:D001241), diazepam (MESH:D003975), biperiden (MESH:D001712), Risperidone (MESH:D018967), Tetrabenazine (MESH:D013747), YGTSS (-), olanzapine (MESH:D000077152), mirtazapine (MESH:D000078785), vortioxetine (MESH:D000078784), sertraline (MESH:D020280), zolpidem (MESH:D000077334), GPi (MESH:D017261), Amisulpride (MESH:D000077582), quetiapine (MESH:D000069348)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943029/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943029/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943029/full.md

---
Source: https://tomesphere.com/paper/PMC12943029